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Abstract. Hospital infection control measures are crucial to tuberculosis (TB) control strategies within settings caring
for human immunodeficiency virus (HIV)–positive patients, as these patients are at heightened risk of developing TB.
Pyrazinamide (PZA) is a potent drug that effectively sterilizes persistent Mycobacterium tuberculosis bacilli. However,
PZA resistance associated with mutations in the nicotinamidase/pyrazinamidase coding gene, pncA, is increasing. A total
of 794 patient isolates obtained from four sites in Lima, Peru, underwent spoligotyping and drug resistance testing. In
one of these sites, the HIV unit of Hospital Dos de Mayo (HDM), an isolation ward for HIV/TB coinfected patients
opened during the study as an infection control intervention: circulating genotypes and drug resistance pre- and post-
intervention were compared. All other sites cared for HIV-negative outpatients: genotypes and drug resistance rates from
these sites were compared with those from HDM. HDM patients showed high concordance between multidrug resistance,
PZA resistance according to the Wayne method, the two most common genotypes (spoligotype international type [SIT]
42 of the Latino American-Mediterranean (LAM)-9 clade and SIT 53 of the T1 clade), and the two most common pncA
mutations (G145A and A403C). These associations were absent among community isolates. The infection control inter-
vention was associated with 58–92% reductions in TB caused by SIT 42 or SIT 53 genotypes (odds ratio [OR] = 0.420,
P = 0.003); multidrug-resistant TB (OR = 0.349, P < 0.001); and PZA-resistant TB (OR = 0.076, P < 0.001). In conclusion,
pncA mutation typing, with resistance testing and spoligotyping, was useful in identifying a nosocomial TB outbreak and
demonstrating its resolution after implementation of infection control measures.
INTRODUCTION
Sound hospital infection control measures are critical for
preventing and managing nosocomial tuberculosis (TB) out-
breaks.1,2 This is especially true in wards caring for people
living with human immunodeficiency virus (HIV) infection
due to the heightened risk of TB among immunosuppressed
patients.3 Compounding this problem is the growing threat
of multidrug-resistant tuberculosis (MDRTB), defined as
strains of TB resistant to rifampin and isoniazid, because
patients living with HIV infection and MDRTB infection
have extremely high mortality and require complicated and
expensive treatment.4,5
Despite having a successful community-based national TB
program since the 1990s,6 hospital TB infection control in
Peru has proven challenging.7 Peruvian national surveillance
data from 2012 estimated that 3.9% of new TB cases were
caused by MDRTB; only 18% of TB patients knew their HIV
status, and only 17% of patients living with HIV infection
were tested for TB.8 In Lima, Peru’s capital, a study by
Campos and others found that 35 of 81 (43%) HIV/TB
coinfected patients sampled from 10 local hospitals between
1999 and 2000 were infected with MDRTB.9
Pyrazinamide (PZA) resistance is another important factor
in TB control. PZA facilitates eradication of persistent bacteria
and thus its incorporation into drug regimens is key to short-
ening treatment duration.10–12 PZA resistance has been shown
to be associated with mutations in the pyrazinamidase (PZAse)
coding gene, pncA.13,14
In the HIV ward of Lima’s Hospital Dos de Mayo (HDM),
we studied the utility of pncA mutation typing, in tandem
with phenotypic resistance testing and spoligotyping, to detect
nosocomial outbreaks and inform the hospital’s new infection
control practices.
METHODS
Study design. Patient recruitment. An anonymized TB
strain bank was compiled from clinical research studies that
enrolled adults diagnosed with pulmonary TB in Lima, Peru,
between 1999 and 2005. A total of 794 study patient primary
isolates (one per patient) with confirmed culture-positive TB
infection were opportunistically spoligotyped from the follow-
ing four cohorts: 1) 241 of 282 study inpatients from the
HDM HIV unit, 2) 329 of 385 study outpatients from Hospital
Maria Auxiliadora, 3) all 155 unselected National TB Control
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Program study patients from 10 government clinics in north
Lima, and 4) all 69 National TB Control Program study
patients selected for high risk of TB or MDRTB from five
government clinics in east Lima. Study recruitment has been
previously reported,5,15–17 and all study protocols and consent
forms were approved by the institutional review boards of
Universidad Peruana Cayetano Heredia, Asociación Benéfica
Proyectos en Informatica, Salud, Medicina, y Agricultura,
Regional Ministry of Health of Lima, HDM, and/or the Johns
Hopkins Bloomberg School of Public Health, and all partici-
pants gave informed, written consent.
Infection control. Before 2001, all HIV-positive inpatients
at HDM were admitted to a ward constituting one large room
measuring 35 × 8 × 4.5 m height. Infection control measures
consisted primarily of large windows that facilitated natural
ventilation, and health-care workers in direct contact with
patients were required to use protective N95 respirators. With
the help of donor funds, a new respiratory isolation ward for
all HIV-infected patients with suspected or confirmed TB
opened in 2001, slightly over 2 years into the study, as part of
an effort to improve the hospital’s TB control measures. This
ward separated these patients from their immunosuppressed
HIV-positive TB-negative counterparts for the first time. The
new ward was equipped with a mechanically ventilated nega-
tive pressure air filtration system. Additional control measures
implemented concurrently included relocation of the waiting
area for outpatients to an outdoor space in the adjacent gar-
dens, and mandatory sputum smear microscopy for all patients
with respiratory symptoms at the time of hospitalization.
Further details outlining the design, implementation, impact,
and cost-effectiveness of this intervention are presented in
the accompanying article in this issue. Second-line drugs
were not universally available at HDM until 2004. A sepa-
rate study evaluating the effects of ultraviolet germicidal
light on TB transmission was conducted from 2002 to 2004 in
the isolation ward. For the duration of this study, these lights
were switched off and on for alternate 24-hour periods.18
It is important to note that although we discuss our data
before and after this infection control intervention in both
the HIV-positive HDM inpatients and the HIV-negative out-
patients from other sites, the intervention only took place in
the HIV-positive HDM inpatients, whereas there was no
infection control intervention in the HIV-negative outpatients
from other sites whose data are used solely for simultaneous
comparison of prevalence.
Defining drug resistance. Spoligotyping data were available
for all isolates. Multidrug resistance was determined by
microplate colorimetric19 and microscopic-observation drug-
susceptibility (MODS)15,16,20 assays. Multidrug resistance
data were unavailable for 12 isolates due to issues with the
growth of the isolate in these assays.
PZA resistance was determined by the standard Wayne
test,21 the results of which were available for all but 193 iso-
lates. Although the Wayne test is an indirect biochemical test,
it was shown to be a good predictor of PZA resistance demon-
strated via the BACTEC 460TB and MGIT960 systems
(Becton Dickinson Diagnostics, Sparks, MD) in the 127 isolates
for which these test results were available (Pearson’s correla-
tion coefficient, R = 0.74). In particular, the Wayne test accu-
rately predicted the PZA resistance of our two most prevalent
mutations (13/14 in agreement for D49N and 4/4 in agreement
for T135P) and our wild-type isolates (52/55 in agreement).
A total of 262 isolates, including all confirmed PZA-
resistant strains and almost all MDR (131/135) strains, along
with an equal number of randomly selected drug-susceptible
strains, were tested for mutations in the pncA gene by
DNA sequencing.22
Data analysis. Pearson’s χ2 test for independence was used
to compare categorical variables. Simple logistic regressions
for both MDR and PZA resistance were performed for rele-
vant independent variables such as genotype, HIV status, age,
and sex. Best-fit models were created by backwards selection
to include only those variables with statistical significance in
both the simple and multiple models. Nested models were
compared using the likelihood ratio test. Spoligotype was
defined as an indicator variable to compare each of the five
most prevalent genotypes—spoligotype international type
(SIT) numbers 50, 53, 33, 42, and 1—with all other genotypes
grouped together. The best-fit models were repeated with the
addition of the interaction terms of HIV status on genotype
to examine for potential effect modification. Odds ratios
(ORs) were calculated using logistic regression and were
adjusted for age and gender. All P values were two sided and
P < 0.05 was considered statistically significant. Analysis was
performed using STATA/IC 12.1 software (STATA Corp.,
College Station, TX).
RESULTS
Patients. A total of 794 study patients diagnosed with a new
TB episode with a positive culture had their Mycobacterium
tuberculosis strain spoligotyped.17 All 241 HDM patients were
HIV seropositive (30% of total), and all other patients were
HIV negative or of unknown HIV status (Table 1). The out-
patients of unknown HIV status were assumed to be HIV
negative for the purpose of this analysis because the preva-
lence of HIV infection in Peru was less than 0.5% of the gen-
eral population, and 1.7% of TB patients.5
Genotypes using SIT numbers. Of these 794 isolates,
149 different spoligotypes were identified. The five most
common TB genotypes among all patients were SIT 50 of
the Harlem3 clade (16% of all isolates), SIT 53 of the T1
clade (12%), SIT 33 of the Latino American-Mediterranean
(LAM)-3 clade (8.3%), SIT 42 of the LAM9 clade (7.4%),
and SIT 1 of the Beijing clade (5.5%). Together, these five
genotypes comprised 397 (50%) of the TB isolates (Table 1).
Drug resistance. PZA resistance, defined according to the
Wayne test, was detected in 16% of isolates overall. Of the
MDR isolates tested, 59% were also PZA resistant, com-
pared with just 3.6% of non-MDR isolates tested (Table 1).
MDR and PZA resistance were strongly correlated
(Pearson’s correlation coefficient, R = 0.63). This correlation
was seen even more clearly among HIV-positive inpatients
(R = 0.79), compared with HIV-negative outpatients (R = 0.33).
Simple logistic regressions were performed to examine the
associations of common genotypes, HIV status, age, and sex
with drug resistance. Multiple logistic regression models were
then created using the best-fit methods described in the data
analysis section above. These revealed SIT 42 and SIT 53 to
be the only genotypes to have statistically significant associa-
tions with both MDR and PZA resistance after adjusting for
HIV status. In these models, SIT 42 had 12 times higher odds
of being MDR and 12 times higher odds of PZA resistance
than the less common genotypes, and SIT 53 had 3.8 times
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higher odds of being MDR and 5.0 times higher odds of PZA
resistance. Patients living with HIV infection had 3.6 times
higher odds of being MDR and 4.4 times higher odds of PZA
resistance than patients without HIV infection, independent
of the aforementioned genotypes (all P < 0.001) (Table 2).
Interaction terms between HIV and these genotypes were
also explored but did not improve model fit. The model
examining the interaction of SIT 42 and HIV coinfection on
MDR was the only new model that retained some statistical
significance (Table 2).
pncA mutations. Of the 262 TB isolates examined for pncA
mutations, the two most common were G145A (a D49N
PZAse mutation) and A403C (a T135P PZAse mutation),
found in 12% and 5.3% of examined isolates, respectively. All
32 G145A isolates were of the SIT 42 genotype, and all were
MDR and PZA resistant. Of these isolates, 31 were from the
HDM HIV ward. Likewise, all 15 of the A403C isolates were
of the SIT 53 genotype, MDR, and PZA resistant; 11 of these
were from the HDM HIV ward (Table 3).
The only other common pncA mutation significantly asso-
ciated with MDR and PZA resistance was C309G (a Y103Stop
protein mutation), found in 3.4% of examined isolates. Eight
of nine C309G isolates were MDR and PZA resistant, six of
which were also SIT 53. All nine were from the HDM HIV
ward (Table 3).
ORs of genotype and drug-resistant infection after the
implementation of the infection control intervention. As
described above, an isolation ward for HIV/TB coinfected
patients was opened in the HIV unit of HDM 2 years into
the study as an infection control intervention. Among HDM
patients, the odds of disease caused by MDRTB after the
intervention was reduced by almost two-thirds compared
with the odds before the intervention (OR = 0.35, P < 0.001),
and the odds of PZA-resistant TB disease after the interven-
tion was reduced by over 90% compared with the odds before
the intervention (OR = 0.076, P < 0.001). The odds of TB dis-
ease after the intervention caused by either SIT 42 or SIT 53,
the genotypes with the strongest associations with drug resis-
tance, was reduced by over half (OR = 0.420, P = 0.003). The
odds of TB disease caused by SIT 50, the most common com-
munity strain, increased slightly after the intervention (OR =
1.729, P = 0.271), whereas the odds of disease caused by other
common drug-susceptible community strains such as SIT 33
and SIT 1 were almost entirely unchanged (Table 4).
By comparison, among community patients, the odds of
PZA-resistant TB disease after the intervention increased
only slightly (OR = 1.3, P = 0.7), and the prevalence of each
of the five most common genotypes (SIT 42, 53, 50, 33, and 1)
remained relatively constant, changing by no more than 2.5%
(Table 4). Of interest, however, is that the odds of MDRTB
infection among community patients actually increased after
the intervention by more than 3-fold (OR = 3.7, P = 0.04).
This indicates that as MDRTB infection was becoming less
common in the HIV ward, it was becoming increasingly com-
mon in the community.
Prevalence of SIT 42 over time. Before the intervention,
the highly drug-resistant genotypes SIT 42 and SIT 53 were
present in the HIV ward of HDM. In the first year of the
study, prevalence of both SIT 42 and SIT 53 was much
higher in HDM than in the community (15% versus 3.6%
TABLE 1
Demographic characteristics, drug resistance characteristics, and Mycobacterium tuberculosis genotypes among hospitalized HIV-positive patients
and HIV-negative outpatients
HIV positive n (%) HIV negative n (%)† Total n (%) P value§
Total patients 241 (30) 553 (70) 794 (100)
Demographic characteristics
Age in years, mean (standard deviation) 32 (7.8) 31 (13) 563* 0.4
Age range 18–63 15–78
Gender 792*
Female 49 (21) 241 (44) 290 (37)
Male 190 (80) 312 (56) 502 (63) < 0.001
Drug resistance characteristics¶
PZA resistant 64 (34) 30 (7.3) 94 (16) < 0.001
MDR 82 (35) 53 (9.7) 135 (17) < 0.001
MDR with PZA resistance 62 (78) 15 (30) 77 (59)
pncA mutation present‖ 69 (50) 35 (29) 104 (40) < 0.001
No. of unique spoligotypes 59 (24) 127 (23) 149 (19)
SIT (clade) in order of total prevalence‡
Id. 177 SIT 50 (Harlem3) 25 (10) 105 (19) 130 (16) 0.003
Id. 188 SIT 53 (T1) 41 (17) 57 (10) 98 (12) 0.008
Id. 75 SIT 33 (LAM3) 12 (5) 54 (10) 66 (8) 0.03
Id. 144 SIT 42 (LAM9) 40 (17) 19 (3) 59 (7) < 0.001
Id. 3 SIT 1 (Beijing) 9 (4) 35 (6) 44 (6) 0.1
Id. 161 SIT 47 (Harlem1) 5 (2) 26 (5) 31 (4) 0.08
Id. 130 SIT 1355 (T2) 11 (5) 13 (2) 24 (3) 0.09
Id. 118 SIT 222 (T1) 6 (2) 18 (3) 24 (3) 0.6
Id. 47 SIT 91 (X3) 7 (3) 15 (3) 22 (3) 0.9
All other genotypes 85 (35) 211 (38) 296 (37)
HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; PZA = pyrazinamide; SIT = spoligotype international type;
TB = tuberculosis.
*Missing values (age, N = 231; and gender, N = 2).
†HIV negative or unknown.
‡Phylogenetic clade assigned according to spolDB4 Pasteur database, SIT number given when the clade is represented by a unique prototype as defined in SpolDB4 Pasteur database.
§P value for the Pearson χ2 proportion test at significance level of (α) 5%.
¶MDR test performed in 782 isolates, Wayne test for PZA resistance performed in 601 isolates, 187 of which were HIV seropositive and 130 of which were MDR.
‖pncA mutation data available for 262 isolates, 139 of which were HIV seropositive.
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and 27% versus 12% of cases, P = 0.003 and P = 0.007,
respectively). In the second year, the prevalence of SIT 42 in
HDM increased dramatically to 39% of cases, whereas prev-
alence in the community stayed nearly the same at 3.8% of
cases (P < 0.001).
In the first year of use of the HDM new isolation ward,
prevalence of SIT 42 among inpatients decreased to 29% of
cases, and again the next year to 13% of cases. Prevalence
continued to decrease in the years that followed, and within
3 years of the intervention, SIT 42 was no longer detected in
TABLE 3
HIV status, drug resistance characteristics, and genotype associations of common pncA mutations
Protein mutation DNA mutation HIV+ %§ †HIV− %§ P value‡ Total %§ MDR %¶ P value*
D49N G145A 31 22 1 0.8 < 0.001 32 12 32 100 < 0.001
T135P A403C 11 7.9 4 3.3 0.1 15 5.3 15 100 < 0.001
Y103Stop C309G 9 6.5 0 0.0 0.004 9 3.4 8 89 0.02
K48T A143C 3 2.2 5 4.1 0.4 8 3.1 7 88 0.03
H51R A152G 3 2.2 4 3.3 0.6 7 2.7 3 43 0.7
All others (25 types, ≤ 3 isolates of each) 12 8.6 21 17 0.04 33 13 25 76 0.002
wild type 70 50 88 72 < 0.001 158 60 41 26 < 0.001
Total (with mutation data) 139 100 123 100 262 100 131 50
Total mutations 69 50 35 29 < 0.001 104 40 90 87 < 0.001
Protein mutation DNA mutation PZA resistant* % P value‡ SIT 42 %¶ SIT 53 %¶
D49N G145A 32/32 100 < 0.001 32 100 0 0
T135P A403C 15/15 100 < 0.001 0 0 15 100
Y103stop C309G 8/9 89 < 0.001 0 0 6 67
K48T A143C 0/7 0 0.054 0 0 0 0
H51R A152G 5/7 71 0.035 1 14 0 0
All others (25 types, ≤ 3 isolates of each) 17/31 55 0.009 4 12 4 12
Wild type 11/154 7.1 < 0.001 6 3.8 22 14
Total (with mutation data) 87/255 34 43 16 47 18
Total mutations 76/101 75 < 0.001 37 36 25 24
HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; PZA = pyrazinamide; SIT = spoligotype international type.
*Missing values (Wayne test data for PZA resistance on 255 of 262 isolates with mutation data).
†HIV negative or unknown status.
‡P value for the Pearson χ2 proportion test at significance level of (α) 5%.
§Percentage of total (with mutation data) row.
¶Percentage of total column.
‖Percentage of total column with available PZA resistance data.
TABLE 2
Association between common Mycobacterium tuberculosis genotypes and drug-resistant phenotype adjusted for relevant variables
Independent variable
MDR
Simple logistic regression* Multiple logistic regression† MLR with interaction‡
OR CI P value OR CI P value OR CI P value
SIT 1 (Beijing) 0.69 0.24–2.0 0.5
SIT 33 (LAM3) 0.11 0.01–0.80 0.03
SIT 42 (LAM9) 14 7.30–25 < 0.001 12 6.3–22 < 0.001 2.6 0.83–8.2 0.1
SIT 50 (Harlem3) 0.59 0.29–1.2 0.144
SIT 53 (T1) 3.4 2.0–5.7 < 0.001 3.8 2.2–6.3 < 0.001
HIV status 5.0 3.4–7.4 < 0.001 3.6 2.3–5.5 < 0.001 3.1 2.0–4.8 < 0.001
Age 0.99 0.97–1.0 0.2
Sex 1.5 1.0–2.3 0.045
HIV/SIT 42 interaction 8.5 1.9–38 0.006
Pseudo R2 0.20 0.18
PZA resistance
Simple logistic regression* MLR†
OR CI P value OR CI P value
SIT 1 (Beijing) 0.36 0.05–2.8 0.331
SIT 33 (LAM3) NA
SIT 42 (LAM9) 15 7.9–30 < 0.001 12 5.9–23 < 0.001
SIT 50 (Harlem3) 0.89 0.38–2.1 0.8
SIT 53 (T1) 4.9 2.7–9.1 < 0.001 5.0 2.7–9.3 < 0.001
HIV status 6.7 4.1–11 < 0.001 4.4 2.6–7.4 < 0.001
Age 0.99 0.97–1.0 0.3
Sex 0.94 0.60–1.5 0.8
CI = confidence interval; HIV = human immunodeficiency virus; LAM = Latino American-Mediterranean TB clade; MDR = multidrug resistant; MLR = multiple logistic regression;
OR = odds ratio; PZA = pyrazinamide; NA = not applicable due to model omission, predicts failure perfectly; SIT = spoligotype international type.
*Simple logistic regression using MDR or PZA resistance as dependent variable. An indicator variable for SIT genotype compares each of these five most common SITs against all SITs
other than these five.
†Multiple logistic regression using MDR or PZA resistance as dependent variable and SIT 42 and SIT 53 as independent variables of interest, adjusted for HIV status. Model chosen by
backwards selection until all variables were statistically significant at level of (α) 5%.
‡Multiple logistic regression using MDR as dependent variable and SIT 42, HIV, and an interaction term for HIV multiplied by SIT 42.
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the HDM cohort (Figure 1). During this time, prevalence of
SIT 42 in the community remained fairly constant (Figure 2).
DISCUSSION
The data characterize an outbreak of TB genotype SIT 42
(LAM9 clade), and possibly also SIT 53 (T1 clade), among
inpatients in a hospital HIV ward during a 6-year period.
The high prevalence of SITs 42 and 53 was not observed with
the other TB genotypes circulating in the HDM population,
nor in the community outpatients without HIV infection dur-
ing the same period. Transmission of SITs 42 and 53 decreased
substantially after implementation of the new isolation ward.
This suggests that these two strains were related to the noso-
comial spread of MDR and PZA-resistant TB within the
HDM population, and demonstrates the effectiveness of con-
trol measures such as negative pressure ventilation, use of
rapid diagnostics, and source isolation in this resource-
constrained setting.
The two most common pncA gene mutations in this study,
G145A (D49N PZAse mutation) and A403C (T135P PZAse
mutation), were found exclusively in the SIT 42 and SIT 53
TABLE 4
Characteristics of TB isolates and odds of infection before and after implementation of the new TB infection control intervention in Hospital
Dos de Mayo
HDM patients living with HIV infection and receiving intervention Community patients receiving no intervention§
Before new ward After new ward Before new ward After new ward
N % N % OR* P value† n % n % OR* P value**
Drug resistance
In
te
rv
en
ti
on
MDR 40/78 51 42/157 27 0.35 < 0.001 13/270 4.8 40/277 14 3.7 0.04
PZA 35/47 74 29/140 21 0.076 < 0.001 12/173 6.9 18/241 7.5 1.3 0.7
Genotype
SIT 42 (LAM9) 19 24 21 13 0.51 0.06 10 3.7 9 3.2 0.62 0.5
SIT 50 (Harlem3) 6 7.5 19 12 1.7 0.3 48 18 57 20 0.81 0.5
SIT 53 (T1) 18 23 23 14 0.51 0.07 29 11 28 9.9 1.07 0.9
SIT 33 (LAM3) 4 5.0 8 5.0 1.3 0.7 27 10 27 9.5 0.59 0.2
SIT 1 (Beijing) 3 3.8 6 3.7 0.92 0.9 20 7.4 15 5.3 0.79 0.7
All others 30 38 84 52 1.8 0.04 136 50 147 52 1.6 0.1
Total 80 100 161 100 270 100 283 100
SIT 42 or SIT 53 37 46 44 27 0.42 0.003 39 14 37 13 0.90 0.8
CI = confidence interval; HDM = Hospital Dos de Mayo; HIV = human immunodeficiency virus; MDR = multidrug resistant; OR = odds ratio; PZA = pyrazinamide; TB = tuberculosis;
SIT = spoligotype international type.
*OR comparing odds after to before intervention, adjusted by age and gender, determined by logistic regression.
†P value for the OR coefficient for the intervention.
‡Intervention: use of new TB ward in HDM separating TB and HIV patients began 2 years into the study.
§HIV negative or unknown status.
‡
FIGURE 1. Change in prevalence over time of highly drug-resistant nosocomial outbreak strains SIT 42 and SIT 53 vs. non-drug-resistant pre-
dominant community strain SIT 50 in Hospital Dos de Mayo inpatients living with human immunodeficiency virus infection. Intervention marked
with vertical line. SIT 42 and SIT 53 highly drug-resistant nosocomial outbreak strains. SIT 50 non-drug-resistant predominant community strain.
SIT = spoligotype international type.
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isolates, respectively. All isolates with one of these two muta-
tions were shown to be MDR and PZA resistant; unsurpris-
ingly, SIT 42 and SIT 53 were also shown to be strongly
associated with MDR and PZA resistance among HIV-positive
HDM inpatients. No significant association with drug resis-
tance was found for these two genotypes among HIV-negative
community patients nor in any other common TB genotypes
regardless of HIV status. MDR and PZA resistance were
highly correlated especially among patients living with HIV
infection. However, the association between drug resistance
and these two SIT genotypes remained significant even after
controlling for the confounding of HIV status.
A study using a guinea pig model to examine the airborne
infectiousness of TB in the HIV ward at HDM showed that
a very small number of MDRTB patients were responsible
for the vast majority of TB transmission.23 This could explain
the rapid and sustained transmission of the drug-resistant
SIT 42 and SIT 53 strains within the HIV-positive HDM
population compared with other genotypes.
In several large Peruvian hospitals, inpatients with infec-
tious diseases have historically shared a large open ward
without engineering for air extraction.9 This greatly increases
the likelihood of person-to-person TB transmission.7,24 HDM,
the source of all patients living with HIV infection in this
study, operated under these conditions until use of a new
respiratory isolation ward for TB patients began in 2001,
2 years into this study. This intervention was associated with
a significant decrease in rates of MDRTB, from 56% to 20%
among HIV/TB coinfected patients (see the accompanying
article in this issue). The effectiveness of the intervention is
apparent from the rapid, sustained reduction in transmission
of SIT 42, culminating in a complete cessation of transmis-
sion of this genotype within 3 years of the new ward open-
ing. Transmission of SIT 53 did not decrease immediately
nor stop completely before the end of the study. However,
odds of both MDR and PZA-resistant infection decreased
significantly after the intervention.
Another notable factor is that SIT 53 had a higher preva-
lence than SIT 42 in the HIV-negative community population
throughout the study (10–3.4% of cases, respectively). In fact,
community prevalence of SIT 53 was second only to SIT 50
(Harlem3 clade), a mostly drug-sensitive strain. One possible
explanation for the slower decrease in prevalence of SIT 53
compared with SIT 42 after the intervention is that new TB
infections in HDM before the intervention were mostly due to
intrahospital spread of drug-resistant strains, whereas after the
intervention, new TB infections were no longer dominated by
intrahospital transmission and began to more closely resemble
the distribution seen in the community. This would also explain
the increase in prevalence of SIT 50 in the HIV-positive
HDM population after the intervention: the most common
community strain replaced the dwindling nosocomial strains.
An unexpected trait of our spoligotyping data is the relative
unimportance of the SIT 1 genotype of the Beijing family.
This strain accounted for less than 6% of patients, and showed
no association with drug resistance. This is surprising consider-
ing the historical association between Beijing family strains
and drug resistance.25 A differential evolution of drug resis-
tance might be occurring, without being linked to the men-
tioned genotyping test markers.
To diagnose TB, sputum smear microscopy was mandatory
in all patients with respiratory symptoms who could produce
sputum. Smear microscopy has advantages of being inexpen-
sive and highly specific. However, it is also poorly sensitive
leading to many false-negative results, and it cannot diagnose
drug resistance. The MODS assay was also used in this study
to determine multidrug resistance. This assay has been
shown to be an inexpensive, sensitive, and specific diagnostic
option,15,16,20 and the incorporation of TB drugs into the cul-
ture medium allows for the determination of antimicrobial
FIGURE 2. Change in prevalence over time of five common strains in community outpatients without human immunodeficiency virus infection.
SIT = spoligotype international type.
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sensitivity to rifampin and isoniazid. Recently, it has also
been validated for the detection of extensively drug-resistant
TB.26 The GeneXpert MTB/RIF (Cepheid, Sunnyvale, CA)
machine is another potentially useful diagnostic option that
detects drug resistance very rapidly.27 Hospital TB control
measures should incorporate use of at least one of the avail-
able rapid tools for TB diagnosis and detection of drug resis-
tance, and use this information to separate patients and to
ensure that all patients receive appropriate, effective treat-
ment. The diagnostic tool that is most appropriate for a partic-
ular hospital will depend on factors such as budget, available
laboratory equipment and personnel, and the characteristics
of the patient population.
Limitations of this study include time gaps in data from the
HIV-negative community population, which was most evident
between years 3 and 4, and missing data (Wayne test adminis-
tered to only 601 of 794 isolates, pncA mutation data only
available for 262).
CONCLUSIONS
Lack of effective infection control measures in an HIV ward
favored the ongoing transmission of two highly drug-resistant
TB genotypes, SIT 42 and SIT 53. The pervading resistance
to PZA found to be associated with these two genotypes can
be explained by their strong association with G145A and
A403C pncA mutations, respectively. The installation of a new
respiratory isolation ward at HDM for HIV-positive patients
with suspected or confirmed TB greatly decreased nosocomial
transmission of these drug-resistant TB strains.
We have shown for the first time the utility of mutation typ-
ing when combined with resistance testing and spoligotyping
in detecting and characterizing TB outbreaks. Our findings
also reinforce the importance of implementing hospital infec-
tion control measures, including rapid susceptibility testing
and patient isolation, to prevent the spread of drug-resistant
TB, especially among patients living with HIV.
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